| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Basic Science Investigations |
1 Department of Radiation Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama
2 Department of Medicine, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama
For calculation of radiation dose to the marrow, standard dosimetry for radiopharmaceuticals that do not bind to the marrow includes dose contributions from radioactivity in blood and the remainder of the body. For a pure ß -emitter such as 90Y, marrow dose is usually determined by the blood contribution. However, myelotoxicity from 90Y-antibody therapy often correlates poorly with marrow dose estimated using the blood method. This study proposes a method to address 2 possible factors affecting marrow dose estimates. These include (a) recycled 90Y in bone/marrow space after 90Y-antibody has been processed in the liver and (b) use of the marrow mass of Reference Man for individual patients. Methods: Thirty-three patients with advanced non-small cell lung cancer were treated with 90Y-anti-TAG-72 murine antibody (CC49). TAG-72 is often expressed in epithelial-derived tumors but not in normal marrow. 111In-CC49 was used as a tracer. The marrow doses from blood were calculated on the basis of radioactivity concentrations in blood. Marrow dose in the lumbar vertebrae was estimated from images for 111In-CC49 uptake in L2–L4. In 20 patients who had CT images, trabecular bone volumes of L2–L4 were measured from CT images to estimate patient-specific marrow mass in L2–L4. The fraction of baseline platelet counts at nadir was used as an indicator of myelotoxicity. Results: Marrow dose per unit injected radioactivity estimated from blood was lower than that from L2–L4 uptake values. Prediction of myelotoxicity using marrow dose estimated from blood was poorer than that using injected dose per body surface area (GBq/m2) (r = 0.31 vs. 0.51). Prediction was improved using marrow dose estimated from L2–L4 uptake, assuming the marrow mass of Reference Man (r = 0.67 for n = 33; r = 0.70 for n = 20). Prediction was worse if reference marrow mass was adjusted by body weight (r = 0.56 for n = 33; r = 0.63 for n = 20). Prediction was not improved if adjusted by body surface area or lean body mass but was improved if adjusted by height (r = 0.72 for n = 33; r = 0.78 for n = 20). The best prediction was obtained (r = 0.85 for n = 20) using patient-specific L2–L4 marrow mass estimated from CT. Conclusion: Marrow dose estimated from the blood radioactivity method was not a good predictor of myelotoxicity for non-marrow-targeting 90Y-antibody therapy. Thrombocytopenia in this group of patients correlated much better with dose estimated from lumbar vertebrae imaging and patient-specific marrow mass than with that estimated from GBq/m2 or standard marrow dose based on blood.
Key Words: radioimmunotherapy • bone marrow • dosimetry • toxicity • cancer
This article has been cited by other articles:
|
|
 |
|
  R. F. Meredith, S. Shen, A. Forero, and A. LoBuglio A Method to Correct for Radioactivity in Large Vessels That Overlap the Spine in Imaging-Based Marrow Dosimetry of Lumbar Vertebrae J. Nucl. Med., February 1, 2008; 49(2): 279 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cremonesi, M. Ferrari, C. M. Grana, A. Vanazzi, M. Stabin, M. Bartolomei, S. Papi, G. Prisco, G. Martinelli, G. Paganelli, et al. High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment J. Nucl. Med., November 1, 2007; 48(11): 1871 - 1879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Siegel and M. G. Stabin Mass Scaling of S Values for Blood-Based Estimation of Red Marrow Absorbed Dose: The Quest for an Appropriate Method J. Nucl. Med., February 1, 2007; 48(2): 253 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Brindle, A. A. Trindade, A. P. Shah, D. W. Jokisch, P. W. Patton, J. C. Pichardo, and W. E. Bolch Linear Regression Model for Predicting Patient-Specific Total Skeletal Spongiosa Volume for Use in Molecular Radiotherapy Dosimetry J. Nucl. Med., November 1, 2006; 47(11): 1875 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shen, S. J. DeNardo, C. M. Richman, A. Yuan, C. H. Siantar, R. T. O'Donnell, L. A. Kroger, and G. L. DeNardo Planning Time for Peripheral Blood Stem Cell Infusion After High-Dose Targeted Radionuclide Therapy Using Dosimetry J. Nucl. Med., June 1, 2005; 46(6): 1034 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vallabhajosula, S. J. Goldsmith, K. A. Hamacher, L. Kostakoglu, S. Konishi, M. I. Milowski, D. M. Nanus, and N. H. Bander Prediction of Myelotoxicity Based on Bone Marrow Radiation-Absorbed Dose: Radioimmunotherapy Studies Using 90Y- and 177Lu-Labeled J591 Antibodies Specific for Prostate-Specific Membrane Antigen J. Nucl. Med., May 1, 2005; 46(5): 850 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lassmann, H. Hanscheid, C. Reiners, S. R. Thomas, B. de Keizer, J. M.H. de Klerk, and M. W. Konijnenberg Blood and Bone Marrow Dosimetry in Radioiodine Therapy of Differentiated Thyroid Cancer After Stimulation with rhTSH J. Nucl. Med., May 1, 2005; 46(5): 900 - 901. [Full Text] [PDF]
|
|
|
|
|
|
S. Shen, A. Forero, A. F. LoBuglio, H. Breitz, M.B. Khazaeli, D. R. Fisher, W. Wang, and R. F. Meredith Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC49 Fusion Protein in Patients with Gastrointestinal Malignancies J. Nucl. Med., April 1, 2005; 46(4): 642 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Goldenberg and R. M. Sharkey Radioimmunotherapy of Non-Hodgkin's Lymphoma Revisited J. Nucl. Med., February 1, 2005; 46(2): 383 - 384. [Full Text] [PDF]
|
|
|
|
|
|
S. Pauwels, R. Barone, S. Walrand, F. Borson-Chazot, R. Valkema, L. K. Kvols, E. P. Krenning, and F. Jamar Practical Dosimetry of Peptide Receptor Radionuclide Therapy with 90Y-Labeled Somatostatin Analogs J. Nucl. Med., January 1, 2005; 46(1_suppl): 92S - 98S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. Wessels, W. E. Bolch, L. G. Bouchet, H. B. Breitz, G. L. DeNardo, R. F. Meredith, M. G. Stabin, and G. Sgouros Bone Marrow Dosimetry Using Blood-Based Models for Radiolabeled Antibody Therapy: A Multiinstitutional Comparison J. Nucl. Med., October 1, 2004; 45(10): 1725 - 1733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. de Keizer, A. Hoekstra, M. W. Konijnenberg, F. de Vos, B. Lambert, P. P. van Rijk, C. J.M. Lips, and J. M.H. de Klerk Bone Marrow Dosimetry and Safety of High 131I Activities Given After Recombinant Human Thyroid-Stimulating Hormone to Treat Metastatic Differentiated Thyroid Cancer J. Nucl. Med., September 1, 2004; 45(9): 1549 - 1554. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
